SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-21-053336
Filing Date
2021-10-19
Accepted
2021-10-18 18:49:39
Documents
17
Period of Report
2021-12-10

Document Format Files

Seq Description Document Type Size
1 PROXY STATEMENT def14a1021_180lifesciences.htm DEF 14A 1290526
2 GRAPHIC t180_logo.jpg GRAPHIC 36650
3 GRAPHIC tsirmarc_sig.jpg GRAPHIC 4034
4 GRAPHIC tlawrence_sig1.jpg GRAPHIC 5424
5 GRAPHIC timage_001.jpg GRAPHIC 11671
6 GRAPHIC timage_002.jpg GRAPHIC 11580
7 GRAPHIC timage_003.jpg GRAPHIC 10258
8 GRAPHIC timage_004.jpg GRAPHIC 10361
9 GRAPHIC timage_005.jpg GRAPHIC 11198
10 GRAPHIC timage_006.jpg GRAPHIC 10855
11 GRAPHIC timage_007.jpg GRAPHIC 9519
12 GRAPHIC timage_008.jpg GRAPHIC 9448
13 GRAPHIC timage_009.jpg GRAPHIC 9484
14 GRAPHIC timage_010.jpg GRAPHIC 3075
15 GRAPHIC timage_011.jpg GRAPHIC 2766
16 GRAPHIC timage_012.jpg GRAPHIC 2047
17 GRAPHIC timage_013.jpg GRAPHIC 3517
  Complete submission text file 0001213900-21-053336.txt   1503103
Mailing Address 830 MENLO AVENUE, SUITE 100 MENLO PARK CA 94025
Business Address 830 MENLO AVENUE, SUITE 100 MENLO PARK CA 94025 650-507-0669
180 Life Sciences Corp. (Filer) CIK: 0001690080 (see all company filings)

IRS No.: 813832378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38105 | Film No.: 211329228
SIC: 2834 Pharmaceutical Preparations